Literature DB >> 9091153

Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience.

T Sasajima1, Y Kubo, M Inaba, K Goh, N Azuma.   

Abstract

OBJECTIVES: The role of bypass to the distal arteries for patients with Buerger's disease (thromboangiitis or TAO) remains controversial because of the high incidence of graft failure. We retrospectively reviewed the results of 71 bypasses to evaluate their efficacy.
MATERIALS AND METHODS: We performed 71 autogenous vein bypasses in 61 patients with TAO. Of the patients, 97% were heavy smokers. The indications for surgery were claudication in 41%, and ischaemic ulcer or gangrene in 59%. Of the bypasses 85% were to the crural arteries or to the arteries below the ankle. The grafts used were 53 single saphenous veins, and 18 venovenous composite grafts.
RESULTS: There were 38 graft failures, the main causes including anastomosis to a diseased artery, disease progression (which occurred in smokers after surgery), and vein graft stenosis. Of 38, 10 were restored to patency by revision surgery. Primary and secondary patency rates were 48.8% and 62.5% at 5 years, and 43.0% and 56.3% at 10 years, respectively. The patency rates of the postoperative non-smoking group was significantly higher than that of the smoking group (66.8% vs. 34.7%, p < 0.05). Thirty-six patients (59%) had successful revascularisation and returned to full-time work. However, of 28 with secondary failure, 11 underwent amputation, while 14 had persistent disabling claudication.
CONCLUSION: Bypass to the distal arteries is an effective treatment for TAO patients, and the long-term patency is quite satisfactory as long as patients stop smoking.

Entities:  

Mesh:

Year:  1997        PMID: 9091153     DOI: 10.1016/s1078-5884(97)80017-2

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  24 in total

1.  Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report.

Authors:  Joaquin De Haro; Aurora Florez; Jose Luis Fernandez; Francisco Acin
Journal:  BMJ Case Rep       Date:  2009-05-12

2.  Buerger's Disease; Any Current Advances?

Authors:  Yong-Bok Koh
Journal:  Ann Vasc Dis       Date:  2008-10-24

3.  Fate of ischemic limbs in patients with Buerger's disease based on our 30-year experience: does smoking have a definitive impact on the late loss of limbs?

Authors:  Masayuki Sugimoto; Hiroki Miyachi; Hirofumi Morimae; Akio Kodama; Hiroshi Narita; Hiroshi Banno; Kiyohito Yamamoto; Kimihiro Komori
Journal:  Surg Today       Date:  2014-04-26       Impact factor: 2.549

4.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

5.  Extreme distal bypass to improve wound healing in Buerger's disease.

Authors:  Giovanni De Caridi; Mafalda Massara; Simona Villari; Eugenio Martelli; Francesco Spinelli; Raffaele Grande; Lucia Butrico; Stefano de Franciscis; Raffaele Serra
Journal:  Int Wound J       Date:  2014-02-25       Impact factor: 3.315

6.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

7.  Buerger's Disease (Thromboangiitis Obliterans)- Management by Ilizarov's Technique of Horizontal Distraction. A Retrospective Study of 60 Cases.

Authors:  Jagdish Jashwantlal Patwa; Ajay Krishnan
Journal:  Indian J Surg       Date:  2010-12-14       Impact factor: 0.656

8.  Peripheral sympathetic block with therapeutic local anesthesia for the manage-ment of upper limb digital ischemia.

Authors:  A Mahli; D Coskun; K Cosarcan
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

Review 9.  Thromboangiitis obliterans.

Authors:  Gregory Piazza; Mark A Creager
Journal:  Circulation       Date:  2010-04-27       Impact factor: 29.690

10.  Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.

Authors:  S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2018-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.